UNSPSC 51372101: Acetyldihydrocodeine

This classification denotes an opioid receptor agonist with the molecular formula C20H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SGY1T84P34, chemically known as 7,8-dihydrocodeine acetate but generally known as acetyldihydrocodeine, which bears US NIH Compound Identifier 5463874. European Medicines Agency schedules Acetyldihydrocodeine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12719MIG.

World Health Organization schedules acetyldihydrocodeine in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule acetyldihydrocodeine under HS 29391900 and SITC 54141. As of Q4 2014, ACETYLDIHYDROCODEINE remains the US FDA Preferred Term for this commodity. SMILES: O1C2C34C(C(N(CC3)C)CC3C4C1C(OC)CC3)CCC2OC(=O)C.

UNSPSC 51372101 Acetyldihydrocodeine, a Commodity code, shows limited direct relevance to recent state and local procurement activity. The code nominally describes a specific opioid pharmaceutical, but the recent opportunities tagged under it reflect broader pharmaceutical and drug-management procurement that does not align with acetyldihydrocodeine as a discrete product line. Seminole County, Florida has solicited naloxone and safe drug deactivation systems through an IFB, while the Texas Health and Human Services Commission issued an RFI on direct-to-manufacturer pharmacy initiatives, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and OTC products. These opportunities span harm-reduction supplies, pharmacy benefit program redesign, and broad-based generic pharmaceutical contracting rather than procurement of acetyldihydrocodeine itself.

Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions. Activity is concentrated in Florida, Texas, and Minnesota, with MMCAP's cooperative structure extending to Oregon and other participating states. The Seminole County naloxone IFB (IFB60459723LAS) closed July 26, 2023, requiring quarterly deliveries of 1,900 naloxone units and 800 deactivation systems annually with a two-year initial term and one-year renewal option. The Minnesota MMCAP RFP (S1070000015802) for generic pharmaceuticals had a March 26, 2026 proposal deadline, with contract effectiveness on July 1, 2026, and weighted evaluation criteria heavily favoring price competitiveness (75 percent). The Texas HHS RFI (HHS0017013) in April 2026 sought vendor information on direct prescription programs and does not signal imminent procurement of acetyldihydrocodeine as a standalone commodity. The mismatch between the code's nominal scope and the actual procurement activity suggests either tagging inconsistency or that this code sees minimal recent solicitation for its stated product.